Search online for retatrutide or zenagamtide and dozens of websites pop up, each promising fast results. Neither drug has been approved by any regulator in the world. Even so, a thriving trade in black market weight loss drugs has taken hold, and a JAMA Medical News report by Rita Rubin, published on 9 October 2026, shows what buyers may be getting instead.
Why Black Market Weight Loss Drugs Are Selling So Fast
In the United States, 40 per cent of adults have obesity, and many insurers refuse to cover the approved GLP 1 treatments that work. Michael DiStefano, a pharmaceutical outcomes researcher at the University of Colorado, says the demand is “like a perfect storm”. Unapproved products generally cost less than the approved ones, so price pulls people in.
Social media then does the rest. A Public Citizen investigation found hundreds of TikTok and Instagram posts from influencers with millions of followers. These posts praise retatrutide as better than semaglutide, advertise the sites that sell it and show viewers how to dose and inject it. Meanwhile, a person who simply wants to lose 10 pounds will not get a prescription, because doctors reserve these treatments for patients who qualify. Many buyers of these unapproved weight loss therapies have no clinical need to lose weight at all.
The market is not standing still, either. Websites already sell eloralintide, which is still in phase 3 trials, and users talk openly about stacking it with approved drugs.
What Is Really in the Vial?
Buyers of black market weight loss drugs cannot be sure what they are injecting. In Australia, a patient suffered a potentially fatal ruptured oesophagus after using a product sold as retatrutide. The Therapeutic Goods Administration tested it and found a high dose of semaglutide, with no retatrutide at all.
Victoria’s Department of Health also reported six cases of liver toxicity linked to products labelled retatrutide. It urged anyone with itchy skin, dark urine or jaundice to seek medical care.
Researchers at the University of Queensland tested three products that each claimed to hold 10 mg of retatrutide. All three contained the drug, but none matched the label. One held half the stated amount, one held twice as much and one held two thirds more. Traces of lead, copper and zinc turned up too, although the authors said the levels sat well below harmful thresholds. They did not test for sterility or endotoxins.
In the US, Public Citizen counted at least 14 users hospitalised, citing FDA data. The true figure is hard to pin down, because nobody supervises these users and nobody is obliged to report a problem.
Research Purposes Only, Except for the Instructions
Many sites carry a disclaimer saying the product is “for research purposes only” or not for human use. Yet they promise discreet shipping in plain packaging, and some explain how to inject. DiStefano calls the disclaimer legal cover.
Doctors are part of the picture as well. A secret shopper study of 49 telehealth platforms found that 45 prescribed a GLP 1 drug to a simulated patient and 34 mailed it. Another study visited 75 weight loss clinics and medical spas in Oklahoma and West Virginia. One business said it sold a triple agonist but would not name the drug.
Compounders can copy formulas from patent applications and buy base compounds, often imported from China. One Florida clinic even offered retatrutide doses up to 30 mg, which is 2.5 times the highest dose tested in the phase 3 trial.
Enforcement Is Struggling to Keep Up
The FDA has issued 21 warning letters to retatrutide sellers since December 2024, but Reshma Ramachandran of Yale School of Medicine says its power to enforce is limited. A business called Tex Peptides received a letter on 24 August, yet five weeks later its homepage still advertised retatrutide. By late September, no warning letter had named a zenagamtide seller.
Drug makers are stepping in to fight the trade. Eli Lilly filed six new lawsuits in August and asked social media platforms, payment processors and regulators to shut the trade down. Novo Nordisk has filed more than 130 lawsuits over unapproved copies of semaglutide, leading to 90 court judgments. In Mississippi, three licensing boards declared that any medical professional supplying these substances is breaching the rules of practice.
Ivania Rizo of Boston University argues that crackdowns will not fix the demand for these drugs. Better affordability and access to approved care, she says, is what keeps patients away from risky alternatives. She also urges patients to tell their doctors about anything bought online.
The Evidence Still Cannot Justify the Risk
The trial results look striking. In a phase 3 trial of about 2300 adults, those on the top retatrutide dose lost 25 per cent of their body weight over 80 weeks, against roughly 4 per cent on placebo. A review of 38 trials and nearly 26,000 participants put zenagamtide at 24 per cent, retatrutide at 22 per cent and tirzepatide at 19 per cent.
However, those numbers come from controlled trials with tested doses and medical oversight. A meta analysis also found that retatrutide ranked among the least tolerable drugs, based on how many participants quit. The vial in a bedroom fridge offers none of that protection.
Rubin’s report makes the central point clear. The trials involved verified products and close monitoring, while black market weight loss drugs offer only a label. As the Lilly spokesperson put it, what is sold on this market is not medicine.
Sources:

Leave a Reply